Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 897.

https://doi.org/10.1182/blood-2018-99-111531

Published: 2018

Journal Articles

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD

Blood (2017) 130 (Supplement 1): 888.

https://doi.org/10.1182/blood.V130.Suppl_1.888.888

Published: 2017

Journal Articles

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Yueh-wei Shen, MS, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, David D. Chang, MD PhD, James N. Kochenderfer, MD, Margo R. Roberts, PhD

Blood (2015) 126 (23): 4426.

https://doi.org/10.1182/blood.V126.23.4426.4426

Published: 2015

Journal Articles

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Arianne Perez, PhD, Lynn Navale, MS, John M. Rossi, MS, Yueh-wei Shen, MS, Yizhou Jiang, PhD, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, Margo R. Roberts, PhD, David D. Chang, MD PhD, James N. Kochenderfer, MD, Adrian Bot, MD PhD

Blood (2015) 126 (23): 2042.

https://doi.org/10.1182/blood.V126.23.2042.2042

Published: 2015

Journal Articles

Truncated Cell-Surface CD19 As a Conditional Suicide Switch For Adoptive T Cell Immunotherapy

Lihua Elizabeth Budde, MD, PhD, Armen Mardiros, MS, Wen-Chung Chang, MS, Xiuli Wang, MD, PhD, Carolina Berger, MD, Christine Brown, PhD, Stanley R Riddell, MD, Oliver W. Press, MD, PhD, Stephen J. Forman, MD

Blood (2013) 122 (21): 1660.

https://doi.org/10.1182/blood.V122.21.1660.1660

Published: 2013

Journal Articles

Targeting Of Leukemia Stem Cells By Interfering With Niches Using CD44 Variant 6 Chimeric Antigen Receptor Redirected Central Memory T Cells

Xiuli Wang, PhD, ChingLam W Wong, BS, Ryan Urak, MS, Armen Mardiros, MS, Wen-Chung Chang, MS, Ellie Taus, BS, Lihua E Budde, MD, PhD, Julie R Ostberg, Ph.D, Christine Brown, PhD, Stephen J. Forman, MD

Blood (2013) 122 (21): 4497.

https://doi.org/10.1182/blood.V122.21.4497.4497

Published: 2013

Journal Articles

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

Armen Mardiros, Cedric Dos Santos, Tinisha McDonald, Christine E. Brown, Xiuli Wang, L. Elizabeth Budde, Lauren Hoffman, Brenda Aguilar, Wen-Chung Chang, William Bretzlaff, Brenda Chang, Mahesh Jonnalagadda, Renate Starr, Julie R. Ostberg, Michael C. Jensen, Ravi Bhatia, Stephen J. Forman

Blood (2013) 122 (18): 3138–3148.

https://doi.org/10.1182/blood-2012-12-474056

Published: 2013

Includes: Supplemental data

Journal Articles

CD123-Specific Chimeric Antigen Receptor Redirected T Cells Exhibit Potent Cytolytic Activity and Multiple Effector Functions Against Acute Myeloid Leukemia without Altering Normal Hematopoietic Colony Formation in Vitro

Armen Mardiros, MS, Cedric Dos Santos, Ph.D, Tinisha McDonald, BS, Christine Brown, PhD, Xiuli Wang, MD, PhD, Wen-Chung Chang, MS, Julie R Ostberg, Ph.D, Ravi Bhatia, MD, Michael C. Jensen, MD, Stephen J. Forman, MD

Blood (2012) 120 (21): 950.

https://doi.org/10.1182/blood.V120.21.950.950

Published: 2012

NARROW

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Truncated Cell-Surface CD19 As a Conditional Suicide Switch For Adoptive T Cell Immunotherapy

Targeting Of Leukemia Stem Cells By Interfering With Niches Using CD44 Variant 6 Chimeric Antigen Receptor Redirected Central Memory T Cells

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

CD123-Specific Chimeric Antigen Receptor Redirected T Cells Exhibit Potent Cytolytic Activity and Multiple Effector Functions Against Acute Myeloid Leukemia without Altering Normal Hematopoietic Colony Formation in Vitro

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only